Pfizer financials
$28.52−0.70%
Close Sep 30, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 28 | Q1 '26 Mar 29 | Q4 '25 Dec 31 | Q3 '25 Sep 28 | Q2 '25 Jun 29 | Q1 '25 Mar 30 | Q4 '24 Dec 31 | Q3 '24 Sep 29 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Oct 1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $15.03B | $14.45B | $17.56B | $16.65B | $14.65B | $13.71B | $17.76B | $17.70B | $13.28B | $14.88B | $14.57B | $13.49B |
| Gross profit | $10.94B | $10.90B | $12.29B | $12.48B | $10.88B | $10.87B | $11.86B | $12.44B | $9.98B | $11.50B | $7.01B | $4.22B |
| Gross margin | 72.8% | 75.4% | 70.0% | 74.9% | 74.2% | 79.3% | 66.7% | 70.3% | 75.2% | 77.3% | 48.1% | 31.3% |
| Operating income | $3.06B | $4.03B | $2.87B | $3.85B | $3.78B | $3.74B | $2.35B | $4.96B | $1.00B | $4.10B | -$4.29B | -$3.17B |
| Net income | -$248.0M | $2.69B | -$1.65B | $3.54B | $2.91B | $2.97B | $410.0M | $4.46B | $41.0M | $3.12B | -$3.37B | -$2.38B |
| Net margin | −1.6% | 18.6% | −9.4% | 21.3% | 19.9% | 21.6% | 2.3% | 25.2% | 0.3% | 20.9% | −23.1% | −17.7% |
| Diluted EPS | $-0.04 | $0.47 | $-0.29 | $0.62 | $0.51 | $0.52 | $0.07 | $0.78 | $0.01 | $0.55 | $-0.59 | $-0.42 |
| EBITDA | $5.16B | $5.88B | $5.37B | $7.19B | $5.39B | $6.04B | $4.98B | $7.04B | $3.99B | $5.94B | -$1.65B | -$1.39B |
| Operating cash flow | $835.0M | $2.62B | $5.35B | $4.60B | -$582.0M | $2.33B | $6.72B | $6.71B | -$1.78B | $1.09B | $5.24B | $3.46B |
| Free cash flow | $302.0M | $2.18B | $4.50B | $4.00B | -$1.20B | $1.77B | $5.80B | $6.06B | -$2.42B | $387.0M | $4.20B | $2.65B |
| Diluted shares | 5,699.0M | 5,731.0M | 5,722.0M | 5,714.0M | 5,706.0M | 5,710.0M | 5,702.0M | 5,705.0M | 5,696.0M | 5,697.0M | 5,750.0M | 5,646.0M |
Balance sheet
| Period end | Jun 28 | Mar 29 | Dec 31 | Sep 28 | Jun 29 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $976.0M | $1.70B | $1.14B | $1.34B | $1.64B | $1.04B |
| Short-term investments | $10.72B | $11.37B | $12.45B | $13.64B | $11.61B | $19.43B |
| Total debt | $63.19B | $64.45B | $64.80B | $61.71B | $61.80B | $64.35B |
| Total assets | $201.13B | $207.62B | $208.16B | $208.73B | $206.09B | $213.40B |
| Total liabilities | $115.64B | $117.21B | $121.39B | $115.64B | $117.08B | $124.90B |
| Shareholders' equity | $85.49B | $90.40B | $86.78B | $93.10B | $89.01B | $88.50B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology